The Case for Drop-Free Cataract Surgery

Ten years ago, I stopped sending most of my cataract patients home with a bag of topical drops. I remember the exact moment I realized how much this change mattered to patients. A woman in her 60s had returned for her 1-week postoperative visit. Her eyes were healing beautifully on no drops. She had no complaints and was smiling. Her husband, in the room with her, was not. When I told them we were done and there was no drop regimen to start, he stopped me and asked why - not in a curious way but in a wait-a-minute way.

I had performed his cataract surgery 6 months earlier the old way, with three topical medications administered three times a day for 4 weeks. He remembered the cost. He remembered setting phone alarms so he would not miss a dose. He even had a drop count memorized - allegedly 127. Now, he was watching his wife walk out of the same practice after seeing the same surgeon with none of it. Genuinely annoyed, he asked me why she got to skip all that. I told him it was not necessary anymore. He looked at me and said something like, "That can't be right. You're literally placing medication in the eye during surgery one time. How is that the same thing as a month?"

He was not wrong. If I could have compressed 10 years of literature, technical refinement, and quiet confidence into a 30-second explanation in a postoperative hallway, I would have. That conversation captures something I still run into not just with patients but also with colleagues. We are so conditioned to equate more treatment with greater safety and drops with diligence that a better path can feel suspicious. His wife was not getting worse care. She was receiving better, less burdensome care at a lower cost with no meaningful trade-off in outcomes.

Making the Case

If we surgeons are judged by the standard of care in our community, how does that standard ever move? Somebody has to go first. My own protocol has never strayed far from the published evidence, which lets me defend every choice with a citation. The data eventually do the talking for me.

In 2007, roughly 30% of surveyed ASCRS members used any form of intracameral antibiotic. By 2014, that percentage was up to half, and in the most recent survey, it was nearly two-thirds. The use of subconjunctival and sub-Tenon triamcinolone followed a similar arc - from something only a few surgeons used in the 2000s to something increasingly common today. Adoption curves like this rarely shift because of a single dramatic study. They shift because enough of us quietly try it, watch our outcomes, and come back for more.

The next obstacle is not the evidence; it is habit. Handing a patient a prescription is easier than changing a technique, and it keeps the medication cost with the patient rather than the practice. Another common objection is that no US FDA-approved product exists for this indication. Even the topical antibiotic drops most of us currently prescribe, however, are US FDA-approved for bacterial conjunctivitis, not cataract surgery, and no large study has ever shown that topical drops for cataract surgery prevent endophthalmitis.

For drop-free cataract surgery, the evidence runs deep. The 2007 ESCRS study was the first large randomized trial to show that intracameral antibiotics meaningfully reduce the risk of endophthalmitis, and its publication quickly changed practice across Europe.¹ Neal Shorstein, MD, and colleagues at Kaiser Permanente later reported a 22-fold reduction in endophthalmitis rates with intracameral antibiotics.² Studies from India and Sweden reached a similar conclusion in different populations.^3,4

The Benefits for Patients and Practices

A topical drop regimen depends on whether the patient can correctly squeeze a bottle three times a day for a month without missing a dose. With an intraoperative injection, that variable disappears. The medication is delivered correctly, every time, by the person with the most training in the room.

When I inform a patient the week before surgery that there are no drops to buy and no schedule to keep, the anxiety leaves their shoulders. Repeated explanations and anxious calls about missed doses are gone. The time saved and goodwill are real.

Cataract surgery has changed in the past 20 years. Extracapsular extractions are rare, the use of ultrasound energy is way down, incisions are smaller, and femtosecond laser assistance gives some surgeons more precise control. A drop-free postoperative course fits that arc.

Known Frictions

I use a pharmacy whose standards closely mirror commercially available products because inconsistent compounding erodes confidence. I have also noticed a real difference between branded and generic triamcinolone, and I adjust the dilution slightly to achieve the same total dose.

The most common setback I have encountered with drop-free cataract surgery is rebound inflammation, usually 7 to 10 days postoperatively. It generally presents as mild redness or a slight dip in visual acuity. In my experience, roughly one in 15 patients experiences rebound inflammation. It does not resemble an infectious reaction and typically resolves with a short course of topical steroid treatment.

Going Drop-Free Involves Three Steps

Going drop-free involves three separate decisions, each with its own evidence base. I did not make all three at once but pursued the following path (see My Current Protocol for the specific concentrations, volumes, placement, and patient-selection criteria I use).

Step No. 1: Trust the Antibiotic Data - and Know When to Make an Exception

Intracameral moxifloxacin has been shown in multiple large studies to reduce the risk of endophthalmitis from roughly one in 3,000 eyes to approximately one in 8,000. That is not a marginal improvement. Critically, layering a topical antibiotic on top of the intracameral dose has not shown additional benefit in many studies.⁵ In some cohorts, it has actually trended toward higher risk, although the reason for this trend is uncertain.

The exception is not a data problem; it is a patient problem. Patients with severe lid disease, significant lid laxity, or chronic blepharitis should receive topical drops in addition to an intracameral antibiotic. I also add topical antibiotic drops for patients with a history of anaphylaxis to any fluoroquinolone.

Step No. 2: Get the Steroid Depot Right

Cystoid macular edema (CME) is the complication we all quietly fear, but the evidence for routine postoperative NSAID drops in low-risk eyes is thin. These drops add cost and a bottle to the regimen without a clear benefit in patients at low risk of CME.

Here is the part that took me longer to accept than it should have: one of the standard treatments for established CME is a sub-Tenon or subconjunctival injection of triamcinolone. A steroid depot placed prophylactically at the time of surgery does not just control inflammation; it also proactively delivers the same therapy I would reach for if CME showed up later. The Shorstein data support this idea⁶ by showing lower odds of postoperative macular edema in the groups that received an injection of triamcinolone compared with patients treated with topical steroids alone.

I reserve NSAID drops for genuinely higher-risk eyes - those with a history of CME, epiretinal membrane, diabetic retinopathy, or vein occlusion. Most others do not need this form of treatment.

Step No. 3: Get Precise About Concentration, Volume, Placement, and Exclusion Criteria

Concentration and volume are not interchangeable variables, and they affect tissue differently. A larger volume of a diluted formulation placed posteriorly spreads over a larger surface area, clears faster, and carries a lower risk of IOP elevation than a smaller, denser depot placed anteriorly, even at a similar total steroid dose. I exclude some patients from sub-Tenon triamcinolone, particularly those who may need a rapid steroid taper, such as patients with glaucoma or a history of herpes simplex keratitis. The depot's slow, steady release is an advantage for most patients but makes it the wrong tool for patients who may require a rapid steroid taper.

Conclusion

When transitioning to drop-free cataract surgery, I recommend starting small (eg, half or three-quarters of appropriate cases) and tracking outcomes. Personal data can build confidence, just as published data built mine.